Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

NK cells, and dendritic cells (DCs) within tumor tissues. This finding suggests that conjugate I, born from the fusion of a Pt chemotherapeutic drug and a STING agonist, stands as a promising and ...

The addition of chimeric antigen receptors (CAR) results in NK cells that target antigens found on tumors. Equally, edits that affect the tumor microenvironment or cell persistence will be ...

The polymorphic nature of KIRs and their ligands adds a layer of complexity to NK cell interactions with tumor cells. Moreover, other inhibitory receptors like CD94/NKG2A, PD-1, TIGIT, and TIM-3 ...

LUND, SE / ACCESS Newswire / January 29, 2025 / Alligator Bioscience (STO:ATORX) Publication validates encouraging clinical ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Swedish immuno-oncology firm Alligator Bioscience today announced that clinical data for its 4-1BB agonist, ATOR-1017 ...

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...